Literature DB >> 20074256

The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.

Zhen Zeng1, Yingchuan Li, Zhen Jiang, Chunsheng Wang, BingBing Li, Wei Jiang.   

Abstract

Pulmonary hypertension is a group of diseases comprising vascular constriction and obstructive changes of the pulmonary vasculature. Phosphodiesterase type 5 inhibitors, for example, sildenafil, can alleviate vascular remodeling in the monocrotaline pulmonary hypertension model in rats. We investigate the mechanisms of sildenafil on the pulmonary vascular remodeling of pulmonary hypertension induced by monocrotaline (MCT) in rats. Thirty Sprague-Dawley rats (weighing 200-220 g) were administered with MCT abdominal cavity injection or equivalent volume of normal saline (NS) (which were treated as C group n = 10) to induce pulmonary hypertension model. Fourteen days later, 20 MCT treated rats were randomly fed with sildenafil (25mg/kg/day) or placebo as S, P group (10 rats for each group), respectively. Another 6 weeks later, mean pulmonary artery pressure (mPAP), index of right ventricular hypertrophy (RV/LV+S) of all animals were measured under general anesthesia. Pulmonary tissue was collected to investigate pathological features of pulmonary arteries and to measure protein expression of ERK(1)/ERK(2) and MKP1. After 6 weeks, there were significant elevated mPAP and RV/LV+S in both P and S groups. The ratio of wall thickness to vessel diameter in pulmonary arteries with diameters <200 microm were increased in both P and S groups. But the ratio of wall thickness to vessel diameter was smaller in S group than that in P group. The phosphorylation level of ERK(1)/ERK(2) were elevated in both P and S groups, but the level of phosphorlation ERK(1)/ERK(2) were lower in S group than that in P group. Intriguingly, the expression level of MKP1 was significantly increased in both S and P groups, while it was higher in S group than that in P group. The sildenafil can decrease mPAP and inhibit the progress of pulmonary vascular remodeling in pulmonary hypertension rats. The ERK-MAP kinase signaling pathway might play a role during this process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20074256     DOI: 10.1111/j.1755-5922.2009.00115.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  6 in total

1.  Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.

Authors:  Michael L Paffett; Selita N Lucas; Matthew J Campen
Journal:  Vascul Pharmacol       Date:  2011-11-25       Impact factor: 5.773

Review 2.  Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea.

Authors:  Ayodeji Adegunsoye; Jay Balachandran
Journal:  Mediators Inflamm       Date:  2015-04-05       Impact factor: 4.711

3.  Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK.

Authors:  Jamie L Wilson; Jun Yu; Linda Taylor; Peter Polgar
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

4.  Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt.

Authors:  Tamas Kiss; Krisztina Kovacs; Andras Komocsi; Adrienn Tornyos; Petra Zalan; Balazs Sumegi; Ferenc Gallyas; Krisztina Kovacs
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

5.  The cross talk between cGMP signal pathway and PKC in pulmonary endothelial cell angiogenesis.

Authors:  Zhen Zeng; Ying-Chuan Li; Zhi-Hua Jiao; Jun Yao; Ying Xue
Journal:  Int J Mol Sci       Date:  2014-06-06       Impact factor: 5.923

6.  Total ginsenosides suppress monocrotaline-induced pulmonary hypertension in rats: involvement of nitric oxide and mitogen-activated protein kinase pathways.

Authors:  Na Qin; Wei Yang; Dongxu Feng; Xinwen Wang; Muyao Qi; Tianxin Du; Hongzhi Sun; Shufang Wu
Journal:  J Ginseng Res       Date:  2015-10-22       Impact factor: 6.060

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.